Hold Strides Arcolab: Gaurang Shah

In a chat with ET Now, Gaurang Shah, VP, Geojit BNP Paribas Financial Services shares his views on Strides Arcolab.

ET Now: For people who are holding on to the share of Strides Arcolab, it is released that dividend figure today, 500 crores, $250 million still left in abeyance, we do not know what will happen with that, what would your advise be?

Gaurang Shah: If you ask me on the fundamental, this is one of the stock that we cover under our pharma universe and the kind of dividend that the company has announced is definitely mouth watering but I guess this process does take time. If you are not looking at short to medium term and if you are really looking at long term, then with the kind of product pipeline that they have it definitely augurs well for the company’s future. Some of these lesser known names in the pharma universe has actually gone ahead and performed very well when you compare it with the likes of even Dr Reddy’s or Ranbaxys of the world so we would definitely recommend to hold on to Strides Arcolab from longer term view.